Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 42, Issue 4, 2015, Pages 706-711

  Tappeiner, Christoph ^a,b   Miserocchi, Elisabetta ^c   Bodaghi, Bahram ^d   Kotaniemi, Kaisu ^e   Mackensen, Friederike ^f   Gerloni, Valeria ^g   Quartier, Pierre ^h   Lutz, Thomas ^f   Heiligenhaus, Arnd ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b ST FRANZISKUS HOSPITAL   (Germany)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Department of Rheumatology   (Italy)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Abatacept; Biologicals; Juvenile idiopathic arthritis; Uveitis

Indexed keywords

ABATACEPT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ARTICLE; CATARACT; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; EPIRETINAL MEMBRANE; EYE SYNECHIA; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; MACULAR EDEMA; MALE; PAPILLEDEMA; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA DETACHMENT; RETROSPECTIVE STUDY; UVEITIS; ADOLESCENT; COMPLICATION; TREATMENT OUTCOME;

ABATACEPT; ADOLESCENT; ARTHRITIS, JUVENILE; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS;

EID: 84940520009     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140410     Document Type: Article

References (32)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
2. Kotaniemi K, Aho K, Kotaniemi A. Uveitis as a cause of visual loss in arthritides and comparable conditions. J Rheumatol 2001; 28:309-12.
3. Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefe Arch Ophthal 2006;244:281-90.
4. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K. German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007;46:1015-9.
5. de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003;87:879-84.
6. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol 2003;135:676-80.
7. Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012;32:1121-33.
8. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005;32:362-5.
9. Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007;17:743-8.
10. Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50.
11. Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013;40:74-9.
12. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13:559-75.
13. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
14. Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010;62:821-5.
15. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
16. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
17. Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res 2010;62:1542-51.
18. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802.
19. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis-a case report. J Rheumatol 2008;35:1897-8.
20. Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res 2011;63:307-8.
21. Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefe Arch Ophthal 2011;249:297-300.
22. Heiligenhaus A, Foeldvari I, Edelsten C, Smith JR, Saurenmann RK, Bodaghi B, et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res 2012;64:1365-72.
23. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
24. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
25. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998; 57:38-41.
26. Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, et al. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res 2012;31:182-94.
27. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49.
28. Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 2011;10:482-9.
29. Caspi R. Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res 2008;42:41-50.
30. Shao H, Woon MD, Nakamura S, Sohn JH, Morton PA, Bora NS, et al. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 2001;42:2016-21.
31. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000;165:5041-7.
32. Goldzweig O, Hashkes PJ. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther 2011;5:61-70.